<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="141264">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01944683</url>
  </required_header>
  <id_info>
    <org_study_id>GGF2-CV-1007</org_study_id>
    <nct_id>NCT01944683</nct_id>
  </id_info>
  <brief_title>A Double-Blind Pharmacokinetic Interaction Study Evaluating the Effect of a Single IV Infusion of GGF2 or Placebo on Midazolam Pharmacokinetics in Patients With Heart Failure</brief_title>
  <acronym>GGF2</acronym>
  <official_title>Phase 1b Study of Pharmacokinetic Interaction, Evaluating the Effect of a Single IV Infusion of GGF2 or Placebo on Midazolam Pharmacokinetics in Patients With Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acorda Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acorda Therapeutics</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will examine midazolam pharmacokinetics following single dose administration of 3
      planned dose levels of GGF2.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This drug-drug interaction (DDI) study evaluates the potential effect of intravenously
      administered GGF2 on the elimination kinetics of midazolam.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety and tolerability of GGF2 IV infusion in patients with heart failure assessed by review of Treatment Emergent Adverse Events (TEAE)</measure>
    <time_frame>90 days (± 3 days)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) parameter Area Under the Curve (AUC) of a single dose of midazolam when administered prior to and following a single IV infusion of GGF2 or Placebo</measure>
    <time_frame>Day 1 to Day 7</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of 2D-Echocardiogram (2D-ECHO) or ECHO with contrast</measure>
    <time_frame>Visit 1 (day-14 to day-1) and visits 2-5 (day 8 through day 90 ± 3 days)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of the Six-Minute Walk Test (6MWT)</measure>
    <time_frame>Visit 1 (day-14 to day-1) and visits 3-5 (day 14 through day 90 ± 3 days)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of metabolic testing measuring maximum capacity of body to transport and use oxygen during incremental exercise (VCO2 and VO2 max)</measure>
    <time_frame>Visit 1 (day-14 to day-1) and visits 3-5 (day 14 through day 90 ± 3 days)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of the M.D. Anderson Symptom Inventory (MDASI) score</measure>
    <time_frame>Visit 1 (day-14 to day-1) and visits 3-5 (day 14 through day 90 ± 3 days)</time_frame>
    <safety_issue>No</safety_issue>
    <description>MDASI is a questionnaire asking patients about the severity of their heart disease symptoms and impact of the symptoms on daily functioning during the past 24 hours.
Scale ranges from 0 (sympton has not been present) to 10 (the symptom was as bad as you can imagine it could be).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>GGF2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be randomized to receive GGF2 or Placebo and on study day 3 administered a single IV infusion.
Each patient will receive 5 oral doses of Midazolam syrup on study day 1 and days 4 through 7 respectively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will be randomized to receive GGF2 or Placebo and on study day 3 administered a single IV infusion.
Each patient will receive 5 oral doses of Midazolam syrup on study day 1 and days 4 through 7 respectively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GGF2</intervention_name>
    <arm_group_label>GGF2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <arm_group_label>GGF2</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  If female, must be at least 2 years post-menopausal or have bilateral oophorectomy,
             hysterectomy or documented sterility

          -  If male, must have documented sterility (by verbal report or previous vasectomy), or
             if non-sterile, must agree to use barrier contraception for the entire duration of
             the trial and until 3 months after the last dose of investigational product. Must
             also agree not to donate sperm during the study and up to 3 months after the last
             dose of investigational product

          -  Stable coronary disease without unstable angina or acute coronary syndrome in the
             last 6 months

          -  All cardiac medications, specifically beta-blockers, renin-angiotensin system
             inhibitors, aldosterone antagonists, hydralazine and nitrates are at a stable dose
             (at least 4 weeks) prior to Day 1

        Exclusion Criteria:

          -  Any previous exposure to GGF2 or other neuregulins

          -  Initiation or change of a prescription medication within the 2 weeks prior to Day 1,
             and/or concomitant medication regimen is expected to change during the course of the
             study

          -  Known allergic reaction to midazolam, or any of the components of midazolam syrup
             (including cherry flavoring), or components of GGF2 diluent

          -  Known specific hepatic disease; total bilirubin &gt;2 mg/dL, AST &gt; 100 IU

          -  History of hepatic impairment (hepatitis B and C)

          -  Type I Diabetes

          -  Documented stroke or transient ischemic attack (TIA) within 2 months of study
             enrollment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enrique Carrazana, MD</last_name>
    <role>Study Director</role>
    <affiliation>Acorda Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brendan Daly</last_name>
      <phone>858-657-5267</phone>
      <email>bdaly@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Barry H Greenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orange County Research Center</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noli Raz</last_name>
      <phone>714-263-7323</phone>
      <email>noli.raz@ocresearchcenter.com</email>
    </contact>
    <investigator>
      <last_name>Joel M Neutel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jacksonville Center for Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rachel Starnes, BS</last_name>
      <phone>904-730-0101</phone>
      <email>rstarnes@encoredocs.com</email>
    </contact>
    <investigator>
      <last_name>Michael J Koren, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tulane University School of Medicine</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberta McDuffie</last_name>
      <phone>504-988-0299</phone>
      <email>rmcduffi@tulane.edu</email>
    </contact>
    <investigator>
      <last_name>Patrice Delafontaine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke Clinical Research Unit</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lou Cappoli</last_name>
      <phone>919-684-4888</phone>
      <email>lou.cappoli@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Robert J Noveck, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Orleans Center for Clinical Research (NOCCR)</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Hayzen, RN</last_name>
      <phone>865-305-9100</phone>
      <phone_ext>6</phone_ext>
      <email>chayzen@noccr.com</email>
    </contact>
    <investigator>
      <last_name>William B Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kore Cardiovascular Research Institute</name>
      <address>
        <city>Lexington</city>
        <state>Tennessee</state>
        <zip>38351</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Manns</last_name>
      <phone>731-512-0104</phone>
      <email>koreresearch@deltamedicus.com</email>
    </contact>
    <investigator>
      <last_name>Elie Hage-Korban, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bobbye M Wieman, RN, BBA, CCRP</last_name>
      <phone>615-936-1518</phone>
      <email>bobbye.wieman@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel J Lenihan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 29, 2014</lastchanged_date>
  <firstreceived_date>September 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
